Prof. Dr. Axel Hauschild, on behalf of Philogen, is giving a presentation about the Phase III PIVOTAL study on May 31st, entitled “Phase 3 study (PIVOTAL) of neoadjuvant intralesional Daromun versus immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases”.

Prof. Dr. Lukas Flatz, on behallf of Philogen, is presenting a poster about Philogen’s DUNCAN study on June 1st, entitled “Intralesional administration of L19IL2/L19TNF in high-risk locally advanced basal cell carcinoma or cutaneous squamous cell carcinoma”

Follow the link for more details.